In a cross-sectional study of 48,118 pediatric primary care encounters, e-cigarette-only household exposure was associated with more asthma flares and activity-related symptoms.

DBV filed a BLA for the Viaskin peanut patch in peanut-allergic children aged 4-7, citing phase 3 VITESSE data, and requested priority review.

Brian Vickery, MD, discusses a phase 1 trial evaluating the safety and tolerability of a microneedle stamp designed to deliver peanut protein through the skin.

Aquestive resubmitted its NDA for dibutepinephrine sublingual film Anaphylm, citing new human factors and PK data addressing the FDA's CRL.

This FAQ breaks down the AAP's newest COVID-19, RSV, and influenza recommendations for clinicians who want a quick refresher on what changed for the 2026-2027 season.

XOCOVA gives pediatricians a new oral option to help prevent COVID-19 after exposure in adolescents aged 12 years and older.

At AAP 2026, Peter Lio, MD, discussed distinguishing allergic and inflammatory skin conditions and when pediatricians should seek specialty care.

In national emergency department data from 2005 to 2024, fractures were the most common pediatric e-bike injury, and e-bikes had the second-highest admission rate.